Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy

Neil Elliot Kay, Jeanette E Eckel-Passow, Esteban D Braggio, Scott VanWier, Tait D. Shanafelt, Daniel L. Van Dyke, Diane F Jelinek, Renee C. Tschumper, Thomas Kipps, John C. Byrd, Rafael Fonseca

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

To better understand the implications of genomic instability and outcome in B-cell chronic lymphocytic leukemia (CLL), we sought to address genomic complexity as a predictor of chemosensitivity and ultimately clinical outcome in this disease. We used array-based comparative genomic hybridization (aCGH) with a one-million probe array and identified gains and losses of genetic material in 48 patients treated on a chemoimmunotherapy clinical trial. We identified chromosomal gain or loss in ≥6% of the patients on chromosomes 3, 8, 9, 10, 11, 12, 13, 14, and 17. Higher genomic complexity, as a mechanism favoring clonal selection, was associated with shorter progression-free survival, and predicted a poor response to treatment. Of interest, CLL cases with loss of p53 surveillance showed more complex genomic features and were found both in patients with a 17p13.1 deletion and in the more favorable genetic subtype characterized by the presence of 13q14.1 deletion. This aCGH study adds information on the association between poor trial response and increasing genetic complexity as CLL progresses.

Original languageEnglish (US)
Pages (from-to)161-168
Number of pages8
JournalCancer Genetics and Cytogenetics
Volume203
Issue number2
DOIs
StatePublished - Dec 2010

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Comparative Genomic Hybridization
Chromosomes, Human, Pair 8
Chromosomes, Human, Pair 3
Genomic Instability
Disease-Free Survival
Clinical Trials
Genes
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Biology

Cite this

Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. / Kay, Neil Elliot; Eckel-Passow, Jeanette E; Braggio, Esteban D; VanWier, Scott; Shanafelt, Tait D.; Van Dyke, Daniel L.; Jelinek, Diane F; Tschumper, Renee C.; Kipps, Thomas; Byrd, John C.; Fonseca, Rafael.

In: Cancer Genetics and Cytogenetics, Vol. 203, No. 2, 12.2010, p. 161-168.

Research output: Contribution to journalArticle

@article{cb04e59d868940268cf3c8d4f567f1dc,
title = "Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy",
abstract = "To better understand the implications of genomic instability and outcome in B-cell chronic lymphocytic leukemia (CLL), we sought to address genomic complexity as a predictor of chemosensitivity and ultimately clinical outcome in this disease. We used array-based comparative genomic hybridization (aCGH) with a one-million probe array and identified gains and losses of genetic material in 48 patients treated on a chemoimmunotherapy clinical trial. We identified chromosomal gain or loss in ≥6{\%} of the patients on chromosomes 3, 8, 9, 10, 11, 12, 13, 14, and 17. Higher genomic complexity, as a mechanism favoring clonal selection, was associated with shorter progression-free survival, and predicted a poor response to treatment. Of interest, CLL cases with loss of p53 surveillance showed more complex genomic features and were found both in patients with a 17p13.1 deletion and in the more favorable genetic subtype characterized by the presence of 13q14.1 deletion. This aCGH study adds information on the association between poor trial response and increasing genetic complexity as CLL progresses.",
author = "Kay, {Neil Elliot} and Eckel-Passow, {Jeanette E} and Braggio, {Esteban D} and Scott VanWier and Shanafelt, {Tait D.} and {Van Dyke}, {Daniel L.} and Jelinek, {Diane F} and Tschumper, {Renee C.} and Thomas Kipps and Byrd, {John C.} and Rafael Fonseca",
year = "2010",
month = "12",
doi = "10.1016/j.cancergencyto.2010.09.003",
language = "English (US)",
volume = "203",
pages = "161--168",
journal = "Cancer Genetics and Cytogenetics",
issn = "0165-4608",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy

AU - Kay, Neil Elliot

AU - Eckel-Passow, Jeanette E

AU - Braggio, Esteban D

AU - VanWier, Scott

AU - Shanafelt, Tait D.

AU - Van Dyke, Daniel L.

AU - Jelinek, Diane F

AU - Tschumper, Renee C.

AU - Kipps, Thomas

AU - Byrd, John C.

AU - Fonseca, Rafael

PY - 2010/12

Y1 - 2010/12

N2 - To better understand the implications of genomic instability and outcome in B-cell chronic lymphocytic leukemia (CLL), we sought to address genomic complexity as a predictor of chemosensitivity and ultimately clinical outcome in this disease. We used array-based comparative genomic hybridization (aCGH) with a one-million probe array and identified gains and losses of genetic material in 48 patients treated on a chemoimmunotherapy clinical trial. We identified chromosomal gain or loss in ≥6% of the patients on chromosomes 3, 8, 9, 10, 11, 12, 13, 14, and 17. Higher genomic complexity, as a mechanism favoring clonal selection, was associated with shorter progression-free survival, and predicted a poor response to treatment. Of interest, CLL cases with loss of p53 surveillance showed more complex genomic features and were found both in patients with a 17p13.1 deletion and in the more favorable genetic subtype characterized by the presence of 13q14.1 deletion. This aCGH study adds information on the association between poor trial response and increasing genetic complexity as CLL progresses.

AB - To better understand the implications of genomic instability and outcome in B-cell chronic lymphocytic leukemia (CLL), we sought to address genomic complexity as a predictor of chemosensitivity and ultimately clinical outcome in this disease. We used array-based comparative genomic hybridization (aCGH) with a one-million probe array and identified gains and losses of genetic material in 48 patients treated on a chemoimmunotherapy clinical trial. We identified chromosomal gain or loss in ≥6% of the patients on chromosomes 3, 8, 9, 10, 11, 12, 13, 14, and 17. Higher genomic complexity, as a mechanism favoring clonal selection, was associated with shorter progression-free survival, and predicted a poor response to treatment. Of interest, CLL cases with loss of p53 surveillance showed more complex genomic features and were found both in patients with a 17p13.1 deletion and in the more favorable genetic subtype characterized by the presence of 13q14.1 deletion. This aCGH study adds information on the association between poor trial response and increasing genetic complexity as CLL progresses.

UR - http://www.scopus.com/inward/record.url?scp=78650010643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650010643&partnerID=8YFLogxK

U2 - 10.1016/j.cancergencyto.2010.09.003

DO - 10.1016/j.cancergencyto.2010.09.003

M3 - Article

C2 - 21156228

AN - SCOPUS:78650010643

VL - 203

SP - 161

EP - 168

JO - Cancer Genetics and Cytogenetics

JF - Cancer Genetics and Cytogenetics

SN - 0165-4608

IS - 2

ER -